Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Interest & Investment Income (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Interest & Investment Income for 8 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income rose 104.19% to $1.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.3 million, a 11.52% increase, with the full-year FY2024 number at $3.9 million, down 38.67% from a year prior.
  • Interest & Investment Income was $1.8 million for Q3 2025 at Whitehawk Therapeutics, down from $2.0 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $2.0 million in Q2 2025 to a low of $2672.0 in Q2 2021.
  • A 5-year average of $964594.9 and a median of $983500.0 in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: tumbled 97.39% in 2021, then skyrocketed 13291.67% in 2022.
  • Whitehawk Therapeutics' Interest & Investment Income stood at $12000.0 in 2021, then surged by 13291.67% to $1.6 million in 2022, then decreased by 6.66% to $1.5 million in 2023, then crashed by 54.93% to $676000.0 in 2024, then skyrocketed by 173.67% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Interest & Investment Income are $1.8 million (Q3 2025), $2.0 million (Q2 2025), and $791000.0 (Q1 2025).